Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations

• Główni autorzy: Chen Shi (Autor), Cong Zhang (Autor), Zhiwen Fu (Autor), Jinmei Liu (Autor), Yuanfeng Zhou (Autor), Bao Cheng (Autor), Cong Wang (Autor), Shijun Li (Autor), Yu Zhang (Autor)
• Format: Książka
• Wydane: Elsevier, 2023-06-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Uncommon epidermal growth factor receptor (EGFR) mutations account for 10%-20% of all EGFR mutations in non-small-cell lung cancer (NSCLC). The uncommon EGFR-mutated NSCLC is associated with poor clinical outcomes and generally achieved unsatisfactory effects to the current therapies using standard...